Get started

Value

Integra LifeSciences Holdings | IART | Long at $12.39Integra LifeSciences Holdings Corp NASDAQ:IART manufactures and sells surgical instruments, neurosurgical products, and wound care solutions for neurosurgery, neurocritical care, otolaryngology, orthopedics, and general surgery. The stock has fallen over the past few years due to earnings misses / lowered earnings per share guidance, slow revenue growth, and operational challenges / recalls. But the company has been around since 1989 (endured many ups and downs during that time), has over 4,000 employees, a book value near $20 (undervalued), a forward price-to-earnings between 6x-9x (depending on the source), and revenue growth beyond 2025 and into 2028. Debt is slightly high with a debt-to-equity ratio of 1.2x and a quick ratio near 0.8x (company may have difficulty meeting its short-term obligations with its most liquid assets), it is thus a risky play. But the valuation and potential turnaround should get some attention. From a technical analysis perspective, the stock price has entered and exited my "crash" simple moving average area 3 times now (see green lines). While I think $10 is likely in the near-term, it appears the stock *may* be forming a bottom - especially given the book value is more than 60% from the current price. But, as always, medical device stocks are always a major investment risk, so due diligence is needed. Thus, at $12.39, NASDAQ:IART is in a buy zone with a note regarding the potential for a dip near $10 before a move up. Targets will be kept low for a swing trade. Targets: $15.00 (+21.0%) $16.50 (+33.2%)
NASDAQ:IARTLong
by WorthlessViews
Grounded Lithium - undervalued, strong business modelGrounded Lithium and Denison Mines are exploring and developing direct lithium extraction (DLE) from brines in Western Canada. Exploration is being directly funded via Denison Mines, who has the option to provide funding in exchange for deposit ownership. Their current deposit has an after tax NPV with 8% discount rate of $1B. Grounded Lithium currently owns 70% of the deposit and will, ultimately, own 25% of the deposit ($250M NPV). Assuming Grounded Lithium is bought out by Denison Mines at a rate of 30% of the NPV, Grounded Lithium will be valued at $75M, a 30x increase from their valuation today. This does not include any added value from additional discoveries or other reasons. This is a long play and I do not expect Denison to make an offer until their buy-in phases have completed in 2026-2027.
OTC:GRDAFLong
by nothximgood
"Housing prices in Belgium never go down"In Belgium whenever you talk to people about investing, property is the first thing on everyones mind. People really feel that once you have a job the first thing you should be doing is buy some property because property values 'always go up'. Now, I'm not here to tell you this is not true, or even that this is a bad investment decision. All I want to show that there's more nuance to this debate. So I made this chart which clearly shows that when denominated in gold (money that can't be printed and thus have its value inflated away) housing prices can definitely go down. This chart shows: yellow line: gold in euro's red line: the Belgian Housing Price Index (euro's) +90% purple line: the Belgian Housing Price index (in gold) -70% The way people think about property in Belgium clearly shows that price-inflation is very much a phenomenon with a society-broad psychological impact. I am certainly not the biggest Keynes fan, but his quote seems quite relevant in the context of this chart: "There is no subtler, no surer means of overturning the existing basis of society than to debauch the currency. The process engages all the hidden forces of economic law on the side of destruction, and does it in a manner which not one man in a million is able to diagnose."
OANDA:XAUEUR
by TraderT33
MVRV Demystified: A Guide to Tops, Bottoms & RiskFinancial nerds love to give tools weird names to make them look like fortune-tellers. Some actually are predictive—like grandma’s dreams!🌙 I’m Skeptic from Skeptic Lab , and today we’re talking about MVRV .. First off, it can’t predict the future , but it tells you four key things:🔮 Identifying market tops and bottoms Assessing market sentiment Trading strategies Risk management What is MVRV? 🔍 Imagine you have a box of chocolates. You want to know how many you have and what they’d be worth if everyone decided to buy or sell. MVRV is a number that shows: “How the current value of everyone’s chocolates compares to the price they originally paid.” High MVRV → people are selling chocolates for much more than they paid → expensive market. Low MVRV → people are selling for less than they paid → cheap market, potential buy zone. In short: MVRV is like a green/red light for buying and selling chocolates 🍫🚦. The Formula ➗ Market Value (MV): total value of all coins at current market price. Realized Value (RV): total value based on last on-chain transaction price — a "truer" cost basis, filtering out short-term volatility. Why Z-Score? ✨ MVRV alone sometimes misleads: In bull markets , it can stay high for weeks → fake sell signals. Low MVRV can just be short-term noise. One week after MVRV was introduced, David Puell and Murad Mahmudov created the MVRV Z-Score. It standardizes MVRV against historical mean and volatility, showing if current levels are truly abnormal. Z > 7 → speculative top Z < 0 → deep undervaluation, potential bottom Applications 🎯 Spotting Tops & Bottoms: High MVRV (>3.5) = late bull top Low MVRV (<1) = bear bottom, strong buy Z-Score filters extremes Market Sentiment: High = greed, low = fear → emotional barometer Trading Moves: Long-term: buy <1, hold Medium-term: sell >3.7, buy <1 Timebound MVRV (365d, 60d) shows short vs long-term holder pressure Risk Management: Identifying potential profit zones Checks if BTC is overpriced/undervalued vs RV Works best combined with SOPR, NVT, macro factors Limitations 🌡️ Sensitive to volatility Assumes on-chain movements = sales (not always) Blind to shocks (regulations, macro events) Overvaluation can persist → mistimed sell signals Needs historical data → weak for new coins Not standalone → combine with other metrics Conclusion 📍 MVRV compares Market Value to Realized Value → shows over- or undervaluation Identifies market tops and bottoms Z-Score filters noise, highlights abnormal levels Historically effective in Bitcoin cycles Best used with other metrics for holistic analysis Boost for more Skeptic takes :) 📈 Disclaimer: This article was written for educational purposes only and should not be taken as investment advice.
Education
by SkepticLab
HIVE? Crazy ideaWe had a greater flag stemming from 2023, and when we broke below it signaled lack of faith the market had in this company. Today we are shooting underneath into a new channel, hoping to align with what will be seen as a drawdown before stock pumps. ----------------------------------------------- Fastforward today; balance sheet is clean good exahash rate positive outlook one of the top BTC treasury holdings non american (if thats a plus to you) ----------------------------------------------- Currently I own 3000 shares of this stock and am selling covered calls to 3 dollars, converting the premium and theta into more shares. My impression from the charts in front of me Slow climb to 3 dollars prior to September earnings call After we will see this ticker start to follow and trend along with BTC. I hope to see growth in this company's holdings of BTC and I do not expect them to shed any more at this current time.
NASDAQ:HIVELong
by RJHH
Regeneron Pharmaceuticals | REGN | Long at $502.28Regeneron Pharmaceuticals NASDAQ:REGN stock dropped more than 17% today due to mixed Phase 3 trial results for itepekimab, a potential COPD drug. However, the company has an extensive drug pipeline, raked in over $14 billion last year, and is currently trading at a price-to-earnings of 15x. Debt-to-equity is 0.09x (extremely healthy) and earnings are forecast to grow 7.5% per year. While 2025 is anticipated to be its "worst" earnings year, the outlook through 2028 looks like steady growth in revenue and cash flow. From a technical analysis view, the stocks entered my "crash" simple moving average zone today (currently between $466 and $502). More often than not, this area signals a bottom in the near-term, but it's not guaranteed. I wouldn't be surprised if the $450s-$460s get hit before a reversal if the market shifts negatively - which will be another entry for me. If it moves into my "major" crash zone in the $300s to close more gaps on the daily chart, I will be piling into this stock heavily (like I did with NYSE:UNH ) for a longer-term hold - of course, unless fundamentals change. I'm going to keep my target small unless there is a "major crash" and eye the closing of the nearest price gap on the daily. There is another between $883-$914... Targets: $590 (+17.5%)
NASDAQ:REGNLong
by WorthlessViews
1
TATA MOTORS VALUATION ANALYSIS 🌺Conclusion🌺 Fair value: ₹1,370/share (DCF, FCFF). Upside vs ~₹676: ~+100%. Why: 12% growth, margin normalization to 13%, capex glide to 6%, revenue‑weighted global ERP yielding WACC ~11.1%, terminal growth 4.3%. 💁🏻DCF (FCFF) Highlights🌸 Framework: 5-year FCFF + Gordon terminal. FCFF ramp (₹Cr): 6,541; 20,072; 34,252; 38,362; 42,965. Assumptions: EBITDA 11.5%→13.0%; D&A ~5.3% of revenue; capex 9.0%→7.5%→6.0%; ΔWC base 0; tax ~18.9%. Bridge: PV(FCFF) ~₹0.96–0.98L Cr; PV(Terminal) ~₹4.05–4.15L Cr; EV ~₹5.01–5.13L Cr; less net auto debt ₹13,500Cr; equity ~₹4.88–4.99L Cr; per share ₹1,360–₹1,380. 🧐Other Valuation Lenses 🌸 JLR: EV/Sales ~0.7–0.9x or EV/EBITDA on normalized 10–12% margins (discount to luxury peers). India CV: EV/EBITDA ~6.0–7.5x mid‑cycle. India PV/EV: EV/EBITDA ~10–12x normalized; use EV/Sales when EBIT soft. 🤔Scenarios (Per‑Share)🤔 Best (EBITDA 13.5–14.0%, capex faster to 6%): ₹1,520–₹1,620. Base (EBITDA 13.0%): ₹1,360–₹1,380 (headline ₹1,370). Worst (EBITDA 10.0–11.5%, capex slower to 7%): ₹1,180–₹1,280. ⭐Key Drivers⭐ JLR premium mix (Range Rover/Defender), tariff/FX normalization, China retail. India PV discounting vs ASP/mix; EV unit economics scale-up. CV cycle durability; pricing discipline. Capex cadence and working capital behavior driving cash conversion. ✨Key Numbers✨ WACC ~11.1% (revenue‑weighted ERP, β≈1.30). Terminal growth 4.3%. Shares ~3.68B; net automotive debt ₹13,500Cr. :it's not buy/sell recommendation this report is for info
NSE:TATAMOTORSLong
by Tap_trader
JSW Cement: Company Profile & Sector Analysis 🙀🧐Conclusion 🧐🙀 🤔While JSW Cement demonstrates ambition and operational scale in India’s vibrant cement sector, its financial health is tempered by high leverage and modest returns. Strong governance, strategic debt management, and transparent reporting will be critical as the company seeks market leadership among robust peers. Long-term investors should closely monitor improvements in cash flows and efficiency, given sector opportunities and competitive dynamics. 🧐The cement sector shows strong growth led by robust leaders; JSW Cement is a promising but highly leveraged mid-cap facing profitability and liquidity challenges. Sector fundamentals remain resilient, but JSW’s turnaround depends on prudent financial and governance reforms 🌺🌺About JSW Cement🌺🌺 JSW Cement is a prominent Indian cement manufacturer, recently listed on BSE and NSE in August 2025. The company aims to rapidly expand its production capacity and footprint across key markets with a focus on sustainable manufacturing and innovative processes. 🤯Cement Sector Growth & Future Potential🤯 - India’s cement demand driven by government infrastructure push and urbanization. - Sector CAGR expected at 7-9% over the next five years with rapid capacity additions. - Companies investing in green cement, alternative fuels, and digital operations. - Consolidation and entry of large players signal a highly competitive future market landscape. 🧐Financials Snapshot (FY25)🧐 - Revenue: ₹6,028 crore - Operating Margin: 15.3% - EBITDA Margin: 16% - Net Margin: 1% - Market Cap: ₹7,400 crore - Free Cash Flow: Negative 😶‍🌫️Key Ratios😶‍🌫️ - Debt/Equity Ratio: 2.6 (sector high) - Return on Equity (ROE): 0.6% (below industry average) - Return on Capital Employed (ROCE): 8% - Current Ratio: 0.65 - Dividend Payout: 0% 👷🏻 Peer Analysis👷🏻 - UltraTech Cement, Shree Cement, and Ambuja Cement lead with stronger margins and lower debt. - JSW Cement’s leverage (high debt) impacts profitability and shareholder returns. - Sector leaders maintain ROE and ROCE above 10-13%; JSW lags in these metrics. - Free cash flow in JSW Cement lags behind top peers due to high investment and operational pressures. - Margins are competitive but net profitability is limited compared to industry best. - JSW Cement is positioned as a mid-cap, growth-oriented player with room for efficiency improvement. - Company’s focus on expansion adds long-term growth potential. - Peer companies show higher liquidity and sustainable dividend payout records.
NSE:JSWCEMENT
by Tap_trader
Bitcoin’s Power Law Curve — Fairly Valued With Room to RunThis chart applies a Power Law Rainbow Model to Bitcoin using a long-term logarithmic regression fitted to BTC's historical price action. Power laws are mathematical relationships often found in nature, science, and network systems — and Bitcoin is no exception. Rather than relying on arbitrary trendlines, this model fits a curve based on the equation: Price = a × t^b Where: t is the number of days since inception a and b are constants optimized to Bitcoin's growth Bands represent log-scaled standard deviation zones from the curve 🌈 Interpreting the Chart The center white curve reflects Bitcoin's "fair value" according to its adoption-based trajectory. Colored bands represent ±1σ, ±2σ, ±3σ from the model, creating a "valuation rainbow." Historically, Bitcoin's cycle bottoms have touched the lower bands (blue/purple), while euphoria tops align with the upper bands (orange/red). ✅ Current Outlook BTC is trading just under the fair value curve , suggesting it's fairly valued or slightly undervalued from a long-term perspective. This position has historically preceded major upside moves, especially in post-halving environments. From a Smart Money Concepts angle, we're in a potential accumulation or markup phase , with institutional and informed capital likely already positioning. 🧠 Why Power Laws Work for BTC Bitcoin adoption follows network effects — more users = more value — which naturally follows a power law. Unlike linear trends, power law curves scale with time , making them ideal for modeling exponential assets. They offer a more objective long-term valuation framework , avoiding emotional cycle chasing. ⚠️ Disclaimer This is not financial advice . The model reflects historical behavior and is a tool to support long-term perspective — not short-term prediction. Always do your own research and risk management.
INDEX:BTCUSD
by RWCS_LTD
HCA Healthcare | HCA | Long at $299.00NYSE:HCA Healthcare: P/E of 13x, earnings are forecast to grow 6.01% per year; earnings have grown 10.6% per year over the past 5 years, and trading at good value compared to peers and industry. From a technical analysis perspective, it dipped to my selected historical simple moving average area and may represent a buying opportunity to fill the daily price gap up to $394.00. Thus, NYSE:HCA is in a personal buy zone at $299.00. Target #1 = $324.00 Target #2 = $362.00 Target #3 = $394.00
NYSE:HCALong
by WorthlessViews
Lennar Corp | LEN | Long at $116.48Across the US, there is a pent-up demand for housing (for the vast majority of locations). While the media likes to selectively report home sales dropping for certain regions, it is more due to mortgage rates and seasonality than demand. Mortgage rates are anticipated to come down over the next 1-2 years and home builders will step in to pick-up the lack of inventory. Healthy companies like Lennar Corp NYSE:LEN , with a P/E of 8x, dividend of 1.68%, very low debt-to-equity (0.17x), etc are likely to prosper, but always stay cautious with the dreaded "recession" announcement if it creeps in... Thus, at $116.48, NYSE:LEN is in a personal buy-zone. In the near-term, I do see the potential for the price to dip near $100 as tariff and other economic red flags continue to be in focus. Targets: $131.00 $145.00 $157.00 $180.00
NYSE:LENLong
by WorthlessViews
Both Technical and Valuation Signals Points Incoming VolatilityThe DAX has been moving sideways since May, with this flat movement evolving into a triangle formation since June. Price action is contracting, and the index appears to be waiting for a catalyst to determine its next direction. The DAX is currently near the regression line from the November dip, which keeps both upward and downward possibilities open, consistent with the neutral signal from the triangle pattern. From a valuation perspective, the DAX’s forward P/E ratio stands at 16.95x, roughly one standard deviation above its 2009-to-date regression line, making it relatively expensive compared to its own history. The S&P 500 trades at a much higher forward P/E of 24.25x, but that figure is near its own long-term regression line. Since early June, the DAX/S&P 500 ratio has fallen by nearly 10%, significantly reducing the DAX’s relative overvaluation and potentially giving it room for another leg higher. Ultimately, the triangle formation may be the deciding factor. The current upper boundary is at 24,500, and the lower boundary is at 23,490. A break of either could bring volatility back to the DAX, with momentum likely to follow the breakout direction. An upward break could target the 24,400–24,500 zone.
PEPPERSTONE:GER40
by ftdsystem
GENIUS Act Spurs Corporate Stablecoin Ambitions Amid Legal HurdlThe newly enacted GENIUS Act has created a landmark regulatory framework for stablecoins in the United States. The law mandates 1:1 backing, rigorous audits, and full transparency for issuers, effectively opening the door for large-scale corporate entry into the sector. Major corporations — including top banks, retail giants, and global tech firms — are now exploring the launch of their own dollar-backed digital tokens. Others are considering strategic partnerships with established issuers to accelerate their entry into the market. The potential applications range from global remittances to supply chain finance, with the promise of faster settlement, lower fees, and improved liquidity. However, significant challenges remain. The regulatory rollout will be phased and compliance-heavy, requiring ongoing coordination with multiple federal agencies. Businesses must also decide whether to operate on public blockchains like Ethereum or Solana, or develop private networks for greater operational control and security. The stablecoin market is expected to expand rapidly under the new law, but issuers must navigate complex issues around anti-money laundering controls, customer identity verification, and capital reserve management. Striking the right balance between regulatory compliance and market competitiveness will be crucial. Meanwhile, established stablecoin providers are adjusting their strategies to align with the new rules, focusing on building institutional trust while maintaining product scalability. For new entrants, the GENIUS Act represents both an opportunity and a challenge — those who move quickly yet carefully may secure a decisive advantage. As the stablecoin infrastructure matures, regulated token issuance by reputable corporations could drive the next wave of crypto integration into mainstream finance. The companies that master compliance, security, and utility will be the ones to define this new era in digital currency.
CRYPTOCAP:USDCLong
by HCN-News12
1.80 this week Posting this chart to show some obvious short term levels if your trading this is I was lucky enough to get Jan 26 1C for .21. I think TLRY could run to 2 pretty easily based on current momentum. Trump said he was looking into declassification when asked today and has shown support before for rescheduling, decriminalization, and state rights to legalize cannabis. "It could take a few weeks and is very complicated." he said I grabbed safer calls to far out although 100% gain today. The closer dated 1.5 calls are cheap and ran 3x as hard ill be looking to load some tm if chart remains above daily MAs. IF weed actually somehow gets declassified $3 should be easy. Up at $1.09-1.16 overnight would be bullish to hold $1 for entry. 4hr RSI is at 90 so this meme like rally could end abruptly or maybe it wants 1.50 first. Revenue has steadily been growing nothing crazy still not profitable and they have been diluting Gross margin is 29.49%, with operating and profit margins of -13.04% and -266.25%. Plenty of risk 17% short float.
NASDAQ:TLRYLong
by WSMS199
2
Evolent Health | EVH | Long at $9.45While 2025 is expected, and has been, a bad year for Evolent Heath NYSE:EVH , the growth prospects look very, very promising. However, I will caution that the price could almost be cut in half from its current trading value ($9.45) with another poor earnings in 2025. This definitely isn't an "it's only up from here" stock. The price entered my "crash" simple moving area (green lines) twice and a third time could occur before the end of the year ($4-$5 range as of this writeup). Regardless of bottom predictions, earnings for NYSE:EVH are expected to rise from $1.9 billion in 2025 to $3.2 billion in 2028. EPS predicted to rise from $0.26 in 2025 to $1.18 in 2028. Debt-to-equity = 1.2x (okay, below 1 is best), Quick Ratio, or the ability to pays current bills is = 1x (okay, between 1.5 and 3 is best), and bankruptcy risk is relatively high (but reduced interest rates may help). Insiders have purchased over $11 million in shares this year with a cost average (~$23): much higher than it's current trading price. So, while it seems there could be some short-term risks for Evolent Health, the future beyond 2025 is bright (based on company projections). Thus, at $9.45, NYSE:EVH is in a personal buy zone with potential downside risk near $4-5 in the near-term. Targets into 2028: $15.00 (+58.7%) $20.00 (+111.6%)
NYSE:EVHLong
by WorthlessViews
FlySBS Aviations –" Next decade "NSE:FLYSBS 🫰🏻 CONCLUSION 🫰🏻 With strong sector tailwinds, rapid fleet expansion, and clear operational scale-up plans, FlySBS Aviation is well positioned to deliver sustainable positive cash flows and attractive long-term returns, offering meaningful upside for investors as industry demand accelerates 🌸 Company Overview & Industry 🌸 -FlySBS Aviation is a private non-scheduled air charter operator serving B2B & B2C clients including corporates, HNIs, celebrities, and diplomats. -Operates a fleet of 3 owned private jets plus dry/wet lease options to meet demand surges. -The Indian private aviation market is growing rapidly, with an expected CAGR of 8–15% over the next decade 🌸FY2025 Sales (Total Revenue: ₹193.9 Cr)🌸 Private Jet Charters: 94% (₹182 Cr) International Missions: 77% (₹149 Cr) Domestic Charters: 23% (₹44.7 Cr) Medical/Security Operations: 4% (₹8 Cr) Subscription/Leasing: 2% (₹3 Cr) 🌸Financial Highlights (FY21–25)🌸 Revenue CAGR: ~63% Net Profit CAGR: ~70% Operating Margin: 21% Net Profit Margin: 14.7% ROE: 18.9% EPS (FY25): ₹25.47 🌸DCF Valuation Insight🌸🫰🏻 Intrinsic Value: ~₹220 per share Justification: The valuation captures the expected transition from a heavy investment phase with negative free cash flow toward stable and positive cash flow generation. The reliability is moderate, contingent on effective execution of growth plans and capital management aligned with market trends
NSE:FLYSBS
by Tap_trader
Ironwood Pharmaceuticals | IRWD | Long at $0.61Ironwood Pharma NASDAQ:IRWD stock dropped ~89% in the past year due to disappointing Phase 3 Apraglutide trial results, FDA requiring an additional trial, weak Q1 2025 earnings (-$0.14 EPS vs. -$0.04 expected), high debt ($599.48M), and analyst downgrades. So why would I be interested in swing trading this company? The chart. The price has entered my "crash" simple moving average zone, which often results in a reversal - even if temporary. Also, Linzess (GI drug) revenue is steady, and I thoroughly believe that alone pushes the fair value near $0.95, if not higher. Thus, at $0.61, NASDAQ:IRWD is in a personal buy zone with the potential for additional declines before future rise. Target: $0.95 (+55.7%)
NASDAQ:IRWDLong
by WorthlessViews